Alterity Therapeutics Limited ATHE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -102.42% | -21.24% | 27.53% | 32.68% | 37.13% |
| Total Depreciation and Amortization | -13.47% | -14.99% | -16.58% | -12.07% | -6.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 296.81% | 226.80% | 151.04% | 125.37% | 87.25% |
| Change in Net Operating Assets | -450.86% | -496.04% | -193.14% | -133.33% | -111.73% |
| Cash from Operations | -104.64% | -31.79% | 17.89% | 15.06% | 9.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 203.37% | 206.81% | -- | -- | -- |
| Cash from Investing | 203.37% | 206.81% | -- | -121,010.53% | -125,021.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.56% | -73.47% | -425.21% | -636.84% | -1,121.15% |
| Issuance of Common Stock | -52.14% | 60.25% | 581.75% | 444.11% | 319.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 60.05% | -43.28% | -460.76% | -312.83% | -202.18% |
| Cash from Financing | -50.18% | 65.19% | 573.67% | 438.65% | 314.99% |
| Foreign Exchange rate Adjustments | 129.94% | -531.07% | -185.51% | -179.27% | -174.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -83.03% | 317.27% | 657.03% | 671.69% | 725.04% |